drugset / Trial / NCT00076986

The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme

NCT00076986

Phase 3 Completed 300 enrolled INSYS Therapeutics Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the PRECISE trial is to determine whether overall survival duration, safety, and quality of life are improved for patients treated with IL13-PE38QQR compared to patients treated with GLIADEL® Wafer following surgical tumor removal in the treatment of first recurrence of glioblastoma multiforme.

Timeline

Start
2004-02
Primary completion
2007-03
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject carmustine Small molecule Other
Subject cintredekin besudotox Protein / enzyme biologic Other

Indications